GRCE

Grace TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

No material screener or newswire events are stored for this ticker yet.

Sentiment decomposition

-0.3

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

2026-06-18

13%

External coverage

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

2026-04-14

13%

External coverage

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

2026-02-12

13%

External coverage

Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update

2025-11-13

13%

External coverage

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

2025-10-23

13%

External coverage

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

2025-08-12

13%

External coverage

Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update

2025-06-23

13%

External coverage

Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104

2025-04-09

28%

External coverage

As of 2026-06-18 • Updated scheduledSource: News desk